{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T03:27:33Z","timestamp":1768274853793,"version":"3.49.0"},"reference-count":17,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2001,12,25]],"date-time":"2001-12-25T00:00:00Z","timestamp":1009238400000},"content-version":"vor","delay-in-days":1454,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["British Journal of Urology"],"published-print":{"date-parts":[[1998,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\u2002To investigate the efficacy and safety of tolterodine, a new antimuscarinic agent, and define the optimum dosage in patients with symptoms of detrusor instability (urgency, increased frequency of micturition and\/or urge incontinence).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>\u2002A double\u2010blind, placebo\u2010controlled, multicentre study was carried out; after a 1\u2010week run\u2010in period to establish baseline values, 81 patients were randomized to receive placebo or tolterodine 0.5, 1, 2 or 4\u2003mg twice daily for 2\u2003weeks. Micturition (diary) variables, urodynamics and subjective urinary symptoms were assessed after 2\u2003weeks\u2019 treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\u2002A per\u2010protocol analysis of efficacy in 64 patients showed dose\u2010related improvements in recorded micturition and urodynamic variables, e.g. at a dosage of 2\u2003mg twice daily, the frequency of micturition, episodes of incontinence and pad use were reduced by 20%, 46% and 29%, respectively, while the volume at first contraction increased by 89\u2003mL. The 4\u2003mg dosage was associated with a large increase in residual urinary volume and an increased incidence of dry mouth. The incidence of adverse events (mainly mild or moderate antimuscarinic effects) was comparable with placebo at tolterodine dosages of\u22642\u2003mg. No serious adverse events were observed and tolterodine had no clinically significant impact on electrocardiographic or laboratory findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\u2002The results indicate that tolterodine offers an effective treatment for the symptoms of detrusor instability. The optimum dosage appears to be 1\u20132\u2003mg twice daily.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1046\/j.1464-410x.1998.00501.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T02:35:36Z","timestamp":1047350136000},"page":"42-48","source":"Crossref","is-referenced-by-count":117,"title":["Efficacy and safety of tolterodine in patients with detrusor instability: a dose\u2010ranging study"],"prefix":"10.1111","volume":"81","author":[{"family":"Rentzhog","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Stanton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Cardozo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Nelson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Fall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Abrams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2001,12,25]]},"reference":[{"key":"e_1_2_6_2_1","unstructured":"FantlJA NewmanDK CollingJet al.Managing acute and chronic urinary incontinence. Clinical practice guideline. Quick reference guide for clinicians no.\u20032 1996 update.Rockville MD. US Department of Health and Human Services Public Health Service Agency for Health Care Policy and Research. AHCPR Pub. no.\u200396\u20100686 1996"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)92117-6"},{"key":"e_1_2_6_4_1","unstructured":"Royal College of PhysiciansIncontinence. Causes Management and Provision of Services.London: Royal College of Physicians of London 1995"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-198835040-00006"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.1990.tb03512.x"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-199506030-00007"},{"key":"e_1_2_6_8_1","first-page":"433","article-title":"The in vitro pharmacological profile of tolterodine \u2014 a new agent for the treatment of urinary urge incontinence.","volume":"13","author":"Nilvebrant L","year":"1994","journal-title":"Neurourol Urodyn"},{"key":"e_1_2_6_9_1","first-page":"523","article-title":"Interaction of tolterodine with cholinergic muscarinic receptors in human detrusor.","volume":"14","author":"Nilvebrant L","year":"1995","journal-title":"Neurourol Urodyn"},{"key":"e_1_2_6_10_1","first-page":"524","article-title":"Effect of tolterodine on electrically induced contractions of isolated human detrusor muscle from stable and unstable bladders.","volume":"14","author":"Naerger H","year":"1995","journal-title":"Neurourol Urodyn"},{"key":"e_1_2_6_11_1","first-page":"435","article-title":"Tolterodine \u2014 a new agent with tissue effect selectivity for urinary bladder.","volume":"13","author":"Gillberg P\u2010G","year":"1994","journal-title":"Neurourol Urodyn"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.1930140606"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.1930070502"},{"key":"e_1_2_6_14_1","first-page":"308","article-title":"Pharmacological in vitro and in vivo profile of DD 01 \u2014 a major metabolite of tolterodine.","volume":"15","author":"Gillberg P\u2010G","year":"1996","journal-title":"Neurourol Urodyn"},{"key":"e_1_2_6_15_1","unstructured":"Palm\u00e9rL AnderssonL AnderssonT StenbergUDetermination of tolterodine and the 5\u2010hydroxymethyl metabolite in plasma serum and urine using gas chromatography\u2010mass spectrometry.J Pharm Biomed Anal: in press"},{"key":"e_1_2_6_16_1","first-page":"287","article-title":"Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity.","volume":"35","author":"Brynne N","year":"1997","journal-title":"Int J Clin Pharmacol Ther"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.1990.tb14992.x"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)38459-8"}],"container-title":["British Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1464-410x.1998.00501.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1464-410x.1998.00501.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T05:48:48Z","timestamp":1761803328000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1046\/j.1464-410x.1998.00501.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,1]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1998,1]]}},"alternative-id":["10.1046\/j.1464-410x.1998.00501.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1464-410x.1998.00501.x","archive":["Portico"],"relation":{},"ISSN":["0007-1331"],"issn-type":[{"value":"0007-1331","type":"print"}],"subject":[],"published":{"date-parts":[[1998,1]]}}}